| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Diiodotyrosine is a precursor of thyroid hormones. It is formed by the iodination of monoiodotyrosine catalyzed by thyroid peroxidase. It is a substrate for thyroid hormone synthesis.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have included amino acids and derivatives; these substances are beneficial synergistic dietary substances that influence the secretion of anabolic hormones, fuel supply during exercise, mental performance during stress-related tasks, and prevent exercise-induced muscle damage [1].
In vitro, diiodotyrosine is used as a precursor in the study of thyroid hormone biosynthesis. It is a substrate for thyroid peroxidase. It is used in research to study iodine metabolism and thyroid function. |
| ln Vivo |
In vivo, diiodotyrosine is an intermediate in the biosynthesis of thyroid hormones. It is produced in the thyroid gland and coupled with other iodotyrosine residues to form T4 and T3. It is a component of the thyroid hormone synthesis pathway.
|
| Enzyme Assay |
In vitro enzyme assays for diiodotyrosine typically measure its role as a substrate for thyroid peroxidase. The enzyme is incubated with iodide and monoiodotyrosine or diiodotyrosine in the presence of hydrogen peroxide. The formation of T4 and T3 is measured by HPLC or radioimmunoassay.
|
| Cell Assay |
Cell-based assays for diiodotyrosine involve treating thyroid cells with the compound and measuring thyroid hormone synthesis, iodide uptake, and gene expression. The compound's role in thyroid hormone biosynthesis is assessed in appropriate cell models.
|
| Animal Protocol |
In vivo animal studies for diiodotyrosine typically involve administration to animal models to study thyroid hormone biosynthesis and iodine metabolism. Thyroid hormone levels, iodide uptake, and thyroid gland function are assessed.
|
| ADME/Pharmacokinetics |
Dedicated pharmacokinetic data for diiodotyrosine is limited. The compound has a molecular weight of 432.98 g/mol and a molecular formula of C9H9I2NO3. It is a precursor in the production of thyroid hormone.
|
| Toxicity/Toxicokinetics |
Diiodotyrosine is generally considered to have low toxicity as an endogenous metabolite. It is a precursor of thyroid hormone. High doses may affect thyroid function. Appropriate safety precautions should be taken when handling the compound.
|
| References | |
| Additional Infomation |
The product of monoiodotyrosine iodination. In the biosynthesis of thyroid hormones, diiodotyrosine residues are coupled with other monoiodotyrosine or diiodotyrosine residues to form T4 or T3 thyroid hormones (thyroxine and triiodothyronine).
Diiodotyrosine (DIT) is a precursor of thyroid hormone. In the biosynthesis of thyroid hormones, diiodotyrosine residues are coupled with other monoiodotyrosine or diiodotyrosine residues to form T4 or T3 thyroid hormones. It is used as a research tool for studying thyroid hormone biosynthesis and iodine metabolism. |
| Molecular Formula |
C9H9I2NO3
|
|---|---|
| Molecular Weight |
432.98
|
| Exact Mass |
432.867
|
| CAS # |
66-02-4
|
| PubChem CID |
6181
|
| Appearance |
Light brown to brown solid powder
|
| Density |
2.4±0.1 g/cm3
|
| Boiling Point |
410.5±45.0 °C at 760 mmHg
|
| Melting Point |
213°C (rough estimate)
|
| Flash Point |
202.1±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.748
|
| LogP |
2.26
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
227
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NYPYHUZRZVSYKL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H9I2NO3/c10-5-1-4(2-6(11)8(5)13)3-7(12)9(14)15/h1-2,7,13H,3,12H2,(H,14,15)
|
| Chemical Name |
2-amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid
|
| Synonyms |
NSC-208959; NSC 208959; Diiodotyrosine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3096 mL | 11.5479 mL | 23.0958 mL | |
| 5 mM | 0.4619 mL | 2.3096 mL | 4.6192 mL | |
| 10 mM | 0.2310 mL | 1.1548 mL | 2.3096 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
